Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,708.95 today based on a price of $111.70 for GILD at the time of writing.

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.

Shares of Gilead Sciences Inc. GILD rose 1.60% to $107.62 Thursday, on what proved to be an all-around great trading session ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P 500’s modest 2% gain.

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD stock is a strong buy.